FDA warning 30 telehealth sites over compounded GLP-1 marketing
Posted by tiredmira in Weight Loss & Metabolic - 3 points, 4 comments.
PharmTech has a piece on the FDA sending out 30 warning letters to telehealth companies for shady marketing around compounded semaglutide and tirzepatide. Basically the feds are cracking down on the telehealth GLP-1 space, which honestly feels overdue.
What gets me is how many of these places were running ads that made compounded stuff sound basically identical to the brand name versions. If you have ever been tempted by a $199 monthly "same as Ozempic" pitch, this is why it pays to slow down and read what is actually in the vial. I get that brand pricing is brutal, but marketing compounds as interchangeable with the real thing is just not it.
Curious if anyone here has actually seen the warning letters change anything on the telehealth side, or if it just pushes the marketing language around. Have any of you switched providers because of stuff like this?
Comments
- tracker_jade: I work with patients who have gotten sucked into those $199 deals and honestly, most of them had no idea what they were actually injecting until they came in for bloodwork and we figured out nothing was tracking the way it should. The marketing is predatory and the "same as Ozempic" language is straight-up misleading when the actual compound can be wildly different in bioavailability and purity. To answer your question though, I have not personally seen it change much on the ground yet. The peo
- tiredmira: That's the part that kills me, the awareness gap. The FDA puts out warning letters and most patients using these services never even hear about it, which kind of defeats the whole point of the crackdown. Did the ones you worked with ever switch to a more transparent provider after finding out nothing was tracking right, or did they just kind of shrug and keep going? Would be curious if the bloodwork revelation was enough to make them reevaluate where they were getting their stuff.
- grinder265: Ngl, I’ve seen a few runners grab those cheap semaglutide pens online and later show up with weird GI stuff and flat labs. Makes me wonder how many actually got the right peptide vs just filler. Anyone else notice off‑label sides when the dose felt off?
- tiredmira: That aligns with what I have been seeing too. When people come in and mention they went through a telehealth service, their labs are often wonky in ways that track back to inconsistent dosing. Compounded stuff is not always wrong, but the variance in what ends up in the vial can be real. The FDA letters basically point out that some of these places were not even hitting the concentration they claimed. The GI stuff especially tracks when the dose is not what you think it is. Escalating too fast
Community discussion - research and educational context only. Not medical advice.